skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon


In Vivo(インビボ)は主に「成長」「イノベーション」「リーダーシップ」「マーケットアクセス」「マーケットインテリジェンス」の5つの観点から世界の医療用医薬品産業のトレンドを取材しています。

世界の開発パイプラインを分析したインフォーマ・ファーマインテリジェンス発行のレポート「Pharma R&D Annual Review 2018」によると、日本は創薬能力では世界第2位、市場規模でも3位につけています。欧米の新薬創出国と比較して劣っているわけではありません。


In Vivoを読むことによって、経営に携わる人々は根拠をもって意思決定をし、リスクをコントロールできるようになります。In Vivoは今日の経営層または新規ビジネス開発担当者にとっては必須のビジネスツールです。

経営戦略・トップマネジメントの視点から研究開発や財務戦略なども含む医薬品産業ニュースを読めるのはIn Vivoだけです。特集記事、注目の人物、KOLの独占インタビュー、業界幹部の異動情報なども充実しています。




  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    In Vivo Outlook 2021 Report

    08 Oct 2021

    In Vivo Outlook 2021 Report

    The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information. 

    Topic deal-trends biopharmaceutical business-strategies

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    How Should Opioid Settlement Dollars Be Spent? It’s Complicated

    By Ben Comer 07 Sep 2021


    Treating opioid addiction successfully requires an individualized approach, and a lot of money. Executives at addiction treatment centers discuss existing barriers in the recovery pathway and the need to destigmatize addiction and mental health disorders.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Critical Insights into Market Access

    18 Aug 2021

    Critical Insights into Market Access

    Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    ‘We Have A Lot Of Work To Do,’ Says Head Of HIV + Hepatitis Policy Institute

    By William Masters 16 Aug 2021


    Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Biotechs Choosing Brazil For Drug Development And Early Sales

    By Mark Ratner 12 Aug 2021


    Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Rising Leaders 2021

    27 May 2021

    Gain insights into managing unexpected events, effectively communicating change, executing crisis management plans, and more. Industry experts share their insights into innovative ways to integrate teams after M&A, manage D&I initiatives, and build strong leadership for a changing workforce.

    Topic Leadership

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, 世界の薬事規制動向&情報を配信

    Manufacturing and Distribution: Challenges and Opportunities

    13 May 2021

    The COVID-19 pandemic has brought about significant manufacturing and distribution challenges and opportunities for Pharma. Seize new opportunities and avoid risk with the strategic commercial and regulatory intelligence you need to stay competitive by subscribing to Pink Sheet and In Vivo.

    Topic strategy

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    COVID-19 Made Its Mark On the R&D Pipeline And Novel Drug Launches In 2020

    By Alex Shimmings 20 Apr 2021


    A new analysis reveals the impact of the coronavirus pandemic on pharma R&D in 2020 in two quarters: the total size of the pipeline and in the number of novel products launched in their first markets.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Pandemic Puts A Spotlight On Counterfeit Drugs

    By William Masters 13 Apr 2021


    As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    The 14 Billion Dose COVID-19 Manufacturing Challenge

    By Andrew McConaghie 25 Mar 2021


    Manufacturing COVID-19 vaccines at unprecedented speed and scale is 2021’s biggest challenge – and mRNA platforms are emerging as the leaders, living up to their promise as the ideal technology for pandemic preparedness.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack

    By Anju Ghangurde 16 Mar 2021


    Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Deal Making Trends 2021

    10 Mar 2021

    Despite the chaos felt in many other sectors during the COVID-19 pandemic, pharma IPOs experienced a banner year in 2020. Understand deal making trends and business strategies as   In Vivo examines the emergence of special purpose acquisition companies (SPACs) in a data-packed infographic

    Topic business-strategies

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    At War With A Pandemic: Manufacturing For Our Lives

    By Joanne Shorthouse 10 Mar 2021


    The rapid development of a vaccine to fight COVID-19 is an effort that will be discussed and admired for centuries to come. The effort to make and deliver the vaccines to those who are most at risk is a battle all of its own. Two manufacturers talk to In Vivo about managing roll out strategies when the whole world is watching.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Pandemic Perspectives: Pharma Must Not Let Its COVID-19 Halo Slip

    03 Mar 2021


    Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit

    27 Jan 2021

    The turn of the year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, this is the time to prophesize on UK medtech’s immediate future.

    Topic Regulation Market Access Medtech-Brexit



William Looney

Editor, Executive Editor, In Vivo


William Looney

William specializes in

  • Biopharma pipeline strategy
  • Biotech
  • Commercial Strategy
  • Market Access
  • Policy and Regulation

40+ years of experience


Cathy Kelly

Editor, Senior editor

Washington DC, USA

Cathy Kelly

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC, USA

Denise Peterson